Patents Examined by Robert Landsman
  • Method for treating psoriasis
    Patent number: 9072725
    Abstract: Methods of treating a patient suffering from psoriasis are disclosed, comprising administration of an antibody binding to interleukin-12 (IL-12).
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: July 7, 2015
    Assignee: Abbvie Biotherapeutics, Inc.
    Inventors: Rolf O. Ehrhardt, Kenneth Hong
  • Fed batch method of making anti-TNF-alpha antibodies
    Patent number: 9073988
    Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: July 7, 2015
    Assignee: AbbVie Inc.
    Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-hsiang D. Chang, Thomas Seewoester
  • Methods of using voltage-gated Hv1 proton channels to detect changes in intracellular pH
    Patent number: 9068018
    Abstract: Nucleic acid and protein sequences relating to a proton channel (Hv1) are disclosed. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the Hv1 gene and protein are disclosed. Also provided are methods of identifying modulators of Hv1 activity, methods of geno typing subjects with respect to Hv1, and methods of diagnosing and treating Hv1-mediated disorders.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: June 30, 2015
    Assignee: Children's Medical Center Corporation
    Inventors: Ian S. Ramsey, Magdalene M. Moran, Jayhong A. Chong, David Clapham
  • Methods of identifying candidate compounds of the human G protein-coupled receptor, GPR50, as modulators of body mass or adiposity
    Patent number: 9068983
    Abstract: The present invention relates to methods of using a G protein-coupled receptor (GPCR) to screen one or more candidate compounds as a modulator of body mass or of adiposity or of percentage body fat in a subject or as a pharmaceutical agent for obesity and conditions related thereto. Inverse agonists and antagonists of the invention are useful as therapeutic agents for the prevention or treatment of obesity and conditions related thereto, including hypertension, insulin resistance, metabolic syndrome, Type 2 diabetes, dyslipidemia, atherosclerosis, coronary heart disease, and stroke. Agonists and partial agonists of the invention are useful as therapeutic agents for the prevention or treatment of disorders ameliorated by increasing body mass including, but not limited to, cachexia.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: June 30, 2015
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Didier Bagnol, Chen W. Liaw
  • Nucleic acid molecules encoding non-naturally occurring T cell receptors and cells thereof
    Patent number: 9068178
    Abstract: A T cell receptor (TCR) having the property of binding to the gp100 YLEPGPVTA peptide-HLA-A2 complex and comprising a TCR alpha variable domain and/or a TCR beta variable domain, characterized in that the domains are mutated relative to a TCR having the extracellular alpha and beta chain sequences SEQ ID NOs: 2 and that the TCR has a binding affinity for, and/or a binding half-life for, the YLEPGPVTA-HLA-A2 complex at least double that of a reference TCR. Embodiments of the invention such as the use of such TCRs in adoptive therapy, and fusions of such TCRs with therapeutic agents are also described.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: June 30, 2015
    Assignee: IMMUNOCORE LTD.
    Inventors: Bent Karsten Jakobsen, Naomi Harwood, Nathaniel Ross Liddy
  • Methods for treating burns-related systemic inflammatory response syndrome
    Patent number: 9066907
    Abstract: A topical preventative medicament against burns-related systemic inflammatory response syndrome containing a low-molecular-weight chaperone as the main active ingredient.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: June 30, 2015
    Assignee: Biofunctional Structure Research Institute, BFSR Co. Ltd.
    Inventors: Masanobu Chinami, Chaker N. Adra
  • Compositions comprising cells expressing cold- and menthol-sensitive receptor (CMR1) polypeptides
    Patent number: 9063125
    Abstract: The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: June 23, 2015
    Assignee: The Regents of the University of California
    Inventors: David Julius, David D. McKemy, Werner M. Neuhausser
  • Method for identifying compounds that modulate a T2R taste receptor
    Patent number: 9063124
    Abstract: The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: June 23, 2015
    Assignee: The Regents of the University of California
    Inventors: Charles Zuker, Jon E. Adler, Nick Ryba, Ken Mueller, Mark Hoon
  • Methods of isolating peptides using surface-free affinity purification
    Patent number: 9056895
    Abstract: The present invention, referred to as Surface-Free Affinity Purification (SFAP), relates to a system and method for purifying low abundance peptides, including digested plasma proteins. SFAP combines the components and processes of Surface-Free Isolation, Specific Competitive Elution, Dual Epitope Isolation and Protective Solvents in the purification of low abundance proteins, all of which may be performed in a single column. This column is a constant volume Diafiltration Column equipped with stirring that can be driven by an HPLC. Digested plasma may be injected into the Diafiltration Column by the HPLC. Immunoglobulins, Specific Competitive Elutants, Protective Solvents are injected in a series of injections that result in the purified peptides bound to the surfaces of a very-low volume hydrophobic reversed phase trap from which they can be easily injected into mass spectrometry detection instruments.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: June 16, 2015
    Assignee: WELLSPRING CLINICAL LAB, INC.
    Inventor: Calvin Wiese
  • Treatment of ocular lesions
    Patent number: 9050310
    Abstract: Methods for the treatment of ocular lesions, particularly diseases of the surface of the eye, selected from pterygium, pinguecula, ocular dysplasia, ocular neoplastic disorders including malignancy of the limbus and eyelids in humans and animals, neurotrophic keratitis, fibrosis of conjunctival drainage blebs in glaucoma and viral disorders of the eye surface are described. Also described are uses and eyedrop formulations for the treatment of eye surface lesions.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: June 9, 2015
    Inventor: Minas Theodore Coroneo
  • Methods for treating psoriasis by administering an antibody which binds an epitope of the p40 subunit of IL-12 and/or IL-23
    Patent number: 9051368
    Abstract: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: June 9, 2015
    Assignee: AbbVie, Inc.
    Inventors: Elliot Keith Chartash, William T. Barchuk, Susan K. Paulson, Joaquin M. Valdes, Alexandra B. Kimball
  • Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
    Patent number: 9046537
    Abstract: The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: June 2, 2015
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Xiaofeng Li, Dakai Liu, Yazhou Zhang, Richard Jin, Riddhi Bhattacharyya, Wei Cheng, James J. Donegan
  • Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same
    Patent number: 9035030
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: May 19, 2015
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Jochen Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Temperature sensitive conjugate compositions
    Patent number: 9035028
    Abstract: This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: May 19, 2015
    Assignees: Emory University, Baker IDI Heart & Diabetes Institute Holdings Ltd.
    Inventors: Elliot L. Chaikof, Karlheinz Peter, Danijal Topcic, Carolyn A. Haller, Wookhyun Kim
  • Interferon-statin combination cancer therapy
    Patent number: 9034310
    Abstract: A method for pharmacological treatment of cancers and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: May 19, 2015
    Inventor: Stephen B. Cantrell
  • Methods of alleviating itch by administering human antibodies to human protease-activated receptor 2
    Patent number: 9028819
    Abstract: The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: May 12, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Andrew J. Murphy, Nicholas J. Papadopoulos, Marc R. Morra, Robert R. Salzler, Michael L. LaCroix-Fralish
  • Antibodies and pharmaceutical compositions thereof which bind urokinase-type plasminogen activator receptor (uPAR)
    Patent number: 9029509
    Abstract: The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the antibodies, and methods involving use of the antibodies or compositions.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: May 12, 2015
    Assignee: The Regents of the University of California
    Inventors: Charles S. Craik, Krishna Sai Duriseti, David H. Goetz
  • Fully human antibodies that bind to VEGFR2 and methods of use thereof
    Patent number: 9029510
    Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
    Type: Grant
    Filed: March 30, 2013
    Date of Patent: May 12, 2015
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
  • Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies
    Patent number: 9028823
    Abstract: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 12, 2015
    Assignee: GITR, Inc.
    Inventors: L. Mary Smith, Grazyna Szymanska, Paul Ponath, Michael Rosenzweig, Jose F. Ponte
  • Methods for treating nicotine addiction and reducing food consumption
    Patent number: 9028808
    Abstract: The present invention relates to a cytokine for use in the treatment and/or control of dependent and/or addictive behavior, in particular addiction and/or dependency to nicotine, food addiction, alcohol addiction and/or sex addiction. The present invention also relates to treatment and/or control of withdrawal and/or symptoms of withdrawal from an addiction, in particular nicotine addiction, food addiction, alcohol addiction and/or sex addiction. The present invention further relates to the induction of loss of interest or aversion to the addictive substance or behavior, such as nicotine, over-indulgence in high-calorie, high-fat foods, and to other behaviors or addictions that are hazardous to the health.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: May 12, 2015
    Assignee: Immunservice GmbH
    Inventor: Edith Huland